KR101557173B1 - 박테리아에서의 쿼럼 센싱의 항체 매개성 파괴 - Google Patents

박테리아에서의 쿼럼 센싱의 항체 매개성 파괴 Download PDF

Info

Publication number
KR101557173B1
KR101557173B1 KR1020107011438A KR20107011438A KR101557173B1 KR 101557173 B1 KR101557173 B1 KR 101557173B1 KR 1020107011438 A KR1020107011438 A KR 1020107011438A KR 20107011438 A KR20107011438 A KR 20107011438A KR 101557173 B1 KR101557173 B1 KR 101557173B1
Authority
KR
South Korea
Prior art keywords
ser
gly
thr
delete delete
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107011438A
Other languages
English (en)
Korean (ko)
Other versions
KR20100102100A (ko
Inventor
김 디 잔다
군나 에프 카우프만
정욱 박
Original Assignee
더 스크립스 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 스크립스 리서치 인스티튜트 filed Critical 더 스크립스 리서치 인스티튜트
Publication of KR20100102100A publication Critical patent/KR20100102100A/ko
Application granted granted Critical
Publication of KR101557173B1 publication Critical patent/KR101557173B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020107011438A 2007-10-25 2008-10-24 박테리아에서의 쿼럼 센싱의 항체 매개성 파괴 Expired - Fee Related KR101557173B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98259307P 2007-10-25 2007-10-25
US60/982,593 2007-10-25

Publications (2)

Publication Number Publication Date
KR20100102100A KR20100102100A (ko) 2010-09-20
KR101557173B1 true KR101557173B1 (ko) 2015-10-05

Family

ID=40580303

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107011438A Expired - Fee Related KR101557173B1 (ko) 2007-10-25 2008-10-24 박테리아에서의 쿼럼 센싱의 항체 매개성 파괴

Country Status (9)

Country Link
US (2) US9394371B2 (OSRAM)
EP (2) EP2842565B1 (OSRAM)
JP (3) JP5581490B2 (OSRAM)
KR (1) KR101557173B1 (OSRAM)
CN (2) CN101835484B (OSRAM)
AU (1) AU2008317331B2 (OSRAM)
CA (2) CA2975568A1 (OSRAM)
ES (1) ES2603061T3 (OSRAM)
WO (1) WO2009055054A2 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2911694A4 (en) 2012-10-26 2016-07-13 Sorrento Therapeutics Inc ANTI-INFECTIOUS BINDING PROTEINS THAT BIND TO AIP2
DE102013211850A1 (de) * 2013-06-21 2014-12-24 Gilupi Gmbh Schnelltest zum Nachweisen von Erregermaterial, insbesondere zur Unterstützung der Diagnose einer Sepsis, sowie Kit und Vorrichtung zur Durchführung eines Sepsistests
SG10201800889SA (en) * 2013-08-01 2018-03-28 Univ Catholique Louvain Anti-garp protein and uses thereof
WO2015100225A1 (en) 2013-12-27 2015-07-02 Novus International Inc. Ethoxylated surfactants
PT3101132T (pt) * 2014-01-29 2021-12-31 Km Biologics Co Ltd Anticorpo humano anti-transtirretina
CN106574258B (zh) 2014-01-29 2021-03-30 Km生物医药股份公司 抗-运甲状腺素蛋白人源化抗体
EP3103808B1 (en) * 2014-02-07 2018-08-22 Miyarisan Pharmaceutical Co., Ltd. Peptide having activity of inhibiting production of toxin by bacterium belonging to genus clostridium
US10821167B2 (en) * 2016-02-02 2020-11-03 Unm Rainforest Innovations VLP-based vaccines for targeting Staphylococcus aureus secreted virulence factors
JP7058638B2 (ja) * 2016-08-11 2022-04-22 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ホスホグリセリン酸ムターゼのペプチド阻害剤および使用方法
AU2018221172A1 (en) * 2017-02-17 2019-09-05 Adimab, Llc Monoclonal antibodies and cocktails for treatment of Ebola infections
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
BR112020003508A2 (pt) * 2017-08-31 2020-09-01 The Regents Of The University Of California polipeptídeo purificado, formulação tópica, polinucleotídeo isolado, vetor, microrganismo recombinante, composição probiótica tópica, composição medicamentosa, e, métodos de tratamento de um transtorno dermatológico, de tratamento de uma doença ou transtorno de pele e para liberação de fármacos através da pele.
US10501539B2 (en) 2017-09-15 2019-12-10 Lentigen Technology Inc. Compositions and methods for treating cancer with anti-CD19 immunotherapy
US10774135B2 (en) 2017-12-22 2020-09-15 Sorrento Therapeutics, Inc. Variant antibodies that bind AIP2
WO2019159864A1 (ja) 2018-02-13 2019-08-22 住友化学株式会社 組成物および成形体
WO2021030550A1 (en) 2019-08-13 2021-02-18 Mccord Darlene E NON-ACTIVATED, AMORPHOUS, pH NEUTRAL, TWO-PART BEDSIDE-READY CLAY DELIVERY SYSTEM THAT TREATS PATHOGEN INFECTIONS IN HUMANS AND ANIMALS
CN111573853B (zh) * 2020-05-29 2020-11-20 南京大学 一种削减生物法处理废水毒性的方法
EP4423197A4 (en) 2021-10-25 2025-08-27 Darlene E Mccord COATED MEDICINAL CLAY COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS AND DELIVERY OF CATION SOURCES AND METHODS OF USE THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69732709T2 (de) * 1996-05-22 2006-06-29 New York University Expressionsblockierung von virulenten faktoren in s. aureus
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
JP2003532698A (ja) * 2000-05-10 2003-11-05 プリンストン ユニバーシティ 細菌の増殖および病理発生を調節するための化合物ならびに方法
US7786257B2 (en) * 2000-12-18 2010-08-31 University Of Kansas Signal-1/signal-2 bifunctional peptide inhibitors
US6463632B2 (en) * 2001-02-07 2002-10-15 Hans Oetiker Ag Maschinen-Und Apparatefabrik Guide arrangement for tightening tool emplacement in hose clamps provided with plastically deformable ears
CN1164612C (zh) 2001-09-11 2004-09-01 四川新泰克控股有限责任公司 人工组合的抗菌工程多肽及其制备方法
ES2382075T3 (es) * 2002-08-13 2012-06-05 Haptogen Ltd Procedimientos para el tratamiento de una enfermedad bacteriana infecciosa con un anticuerpo contra las moléculas señal derivadas de una antilactona o una lactona

Also Published As

Publication number Publication date
EP2211889B1 (en) 2014-08-20
EP2842565B1 (en) 2016-08-24
US20100291093A1 (en) 2010-11-18
EP2211889A4 (en) 2012-01-11
US20170043020A1 (en) 2017-02-16
KR20100102100A (ko) 2010-09-20
US9394371B2 (en) 2016-07-19
WO2009055054A3 (en) 2009-09-03
EP2842565A1 (en) 2015-03-04
CA2975568A1 (en) 2009-04-30
JP6183910B2 (ja) 2017-08-23
ES2603061T3 (es) 2017-02-23
CA2703133A1 (en) 2009-04-30
CN101835484B (zh) 2014-07-16
WO2009055054A2 (en) 2009-04-30
AU2008317331B2 (en) 2013-08-29
CN104211775A (zh) 2014-12-17
JP2014221774A (ja) 2014-11-27
JP5581490B2 (ja) 2014-09-03
JP2018021021A (ja) 2018-02-08
CN101835484A (zh) 2010-09-15
EP2211889A2 (en) 2010-08-04
AU2008317331A1 (en) 2009-04-30
JP2011500814A (ja) 2011-01-06
CA2703133C (en) 2017-09-19

Similar Documents

Publication Publication Date Title
KR101557173B1 (ko) 박테리아에서의 쿼럼 센싱의 항체 매개성 파괴
JP5717582B2 (ja) ポリ−Ｎ−アセチルグルコサミン（ＰＮＡＧ／ｄＰＮＡＧ）結合ペプチドおよびその使用方法
KR101015496B1 (ko) Ｃｌｆａ 단백질에 대한 단일 클론성 항체 및 감염의 치료 또는 예방에 있어서의 사용 방법
KR102039189B1 (ko) 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도
CN108640989B (zh) 可结合并中和b型流感病毒的人类结合分子及其用途
US9371396B2 (en) Anti-CD22 anti-idiotypic antibodies and uses thereof
CN114729033B (zh) 抗α-溶血素的抗体及其应用
KR20110049802A (ko) 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도
KR20190112003A (ko) 항체 분자-약물 접합체 및 이의 용도
CN112672788A (zh) 抗金黄色葡萄球菌凝集因子a(clfa)的抗体
CN114685652A (zh) 针对SARS-CoV-2和SARS-CoV的全人广谱交叉中和抗体及其应用
US8722046B2 (en) Human monoclonal antibodies protective against bubonic plague
CN114685653B (zh) 抗新冠病毒受体结合区域表位中和抗体及其应用
JP4690196B2 (ja) 復活技術によって生成された炭疽菌毒素に対する中和ヒト抗体
KR102467943B1 (ko) 항-rsv 항체 및 이를 포함하는 약학적 조성물
CN113698478B (zh) 抗α-溶血素的抗体及其稳定制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20180903

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20190829

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230925

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230925